LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
Accessnewswire·2026-02-05 23:00
VANCOUVER, BC / ACCESS Newswire / February 5, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company) is pleased to announce that it has commenced Project Phase 2 peptide design activities with Neuland Laboratories Limited ("Neuland") under the parties' existing services agreement (please see news release dated January 8, 2026). Project Phase 2 of the collaboration focuses on the design and optimization of next-generation cell-penetrating peptides intend ...